Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Yen-Fu Chen; Paresh Jobanputra; Pelham Barton; Stirling Bryan; Anne Fry-Smith; Gwyn Harris; RS Taylor

doi:10.3310/hta12110

Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Yen-Fu Chen
, Paresh Jobanputra
, Pelham Barton
, Stirling Bryan
, Anne Fry-Smith
, Gwyn Harris
, RS Taylor

Research output: Contribution to journal › Article

202 Citations (Scopus)

Abstract

The aims of this review are four-fold:

Original language	English
Pages (from-to)	1-+
Journal	Health Technology Assessment
Volume	12
Issue number	11
DOIs	https://doi.org/10.3310/hta12110
Publication status	Published - 1 Jan 2008

Access to Document

10.3310/hta12110

Fingerprint

Dive into the research topics of 'Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation'. Together they form a unique fingerprint.

Cite this

Chen, Y.-F., Jobanputra, P., Barton, P., Bryan, S., Fry-Smith, A., Harris, G., & Taylor, RS. (2008). Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment, 12(11), 1-+. https://doi.org/10.3310/hta12110

@article{7a5b71e32fa54a9481ad1c3795aabb20,

title = "Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation",

abstract = "The aims of this review are four-fold:",

author = "Yen-Fu Chen and Paresh Jobanputra and Pelham Barton and Stirling Bryan and Anne Fry-Smith and Gwyn Harris and RS Taylor",

year = "2008",

month = jan,

day = "1",

doi = "10.3310/hta12110",

language = "English",

volume = "12",

pages = "1--+",

journal = "Health Technology Assessment",

issn = "2046-4924",

publisher = "NIHR Health Technology Assessment Programme",

number = "11",

}

Chen, Y-F, Jobanputra, P, Barton, P, Bryan, S, Fry-Smith, A, Harris, G & Taylor, RS 2008, 'Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation', Health Technology Assessment, vol. 12, no. 11, pp. 1-+. https://doi.org/10.3310/hta12110

Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. / Chen, Yen-Fu; Jobanputra, Paresh; Barton, Pelham et al.
In: Health Technology Assessment, Vol. 12, No. 11, 01.01.2008, p. 1-+.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

AU - Chen, Yen-Fu

AU - Jobanputra, Paresh

AU - Barton, Pelham

AU - Bryan, Stirling

AU - Fry-Smith, Anne

AU - Harris, Gwyn

AU - Taylor, RS

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The aims of this review are four-fold:

AB - The aims of this review are four-fold:

U2 - 10.3310/hta12110

DO - 10.3310/hta12110

M3 - Article

SN - 2046-4924

VL - 12

SP - 1-+

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 11

ER -

Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G et al. Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment. 2008 Jan 1;12(11):1-+. doi: 10.3310/hta12110